Head and Neck Squamous Cell Carcinoma
Conditions
Interventions
Camrelizumab trial group (exposed group):None
Sponsors
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Hospitalized patients histologically confirmed as having Head and Neck Squamous Cell Carcinoma (HNSCC); 2. Aged >=18 years and =3 months; 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; 5. Received at least 2 cycles of Camrelizumab treatment, with or without other anti-tumor drugs; 6. All patients underwent blood cell analysis, blood biochemistry, lipid profile, coagulation function, thyroid function, tumor marker tests, and imaging examinations prior to Camrelizumab infusion, to evaluate anti-tumor efficacy and monitor adverse drug reactions and toxicities; 7. Patients had complete medical records.
Exclusion criteria
Exclusion criteria: 1.Known allergy or intolerance to the study drug; 2.Communication disorders or mental illness; 3.Pregnant or breastfeeding women; 4.Concurrent presence of other types of tumors; 5.Severe primary diseases involving the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems; 6.History of tuberculosis or active pulmonary tuberculosis; 7.Severe autoimmune diseases; 8.Prior organ or hematopoietic stem cell transplantation; 9.Vaccination with live vaccines during the treatment period;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Steady-state plasma concentration of Camrelizumab;Disease Control Rate (DCR);PD-1 gene polymorphism;Objective Response Rate (ORR);Progression-Free Survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Causality assessment of irAEs;Occurrence and grading of immune-related adverse events (irAEs); | — |
Countries
China
Contacts
Public ContactRong Wang
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Outcome results
None listed